Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network

Cancer Investigation

Volumn 21, Issue 1, 2003, Pages 137-147

  Lacombe, D ^a   Butler Smith, A ^b   Therasse, P ^a   Fumoleau, P ^a   Burtles, S ^c   Calvert, H ^c   Marsoni, S ^d   Sessa, C ^d   Verweij, J ^a  

^a EORTC DATA CENTER   (Belgium)

^b European Drug Development Network   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d Southern Europe New Drug Organization Foundation   (Italy)

Author keywords

Cancer research; Clinical trials; European Drug Development Network; New drugs

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BBR 3464; BMS 184476; BMS 310705; C595; CAMPTOTHECIN DERIVATIVE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DNA VACCINE; EPOTHILONE DERIVATIVE; GIMATECAN; GLUFOSFAMIDE; HUMV833; IMATINIB; INDISULAM; INTERCALATING AGENT; IXABEPILONE; LURTOTECAN; MONOCLONAL ANTIBODY; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RUBITECAN; SABARUBICIN; SCH663376; TAXANE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XR5000;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER; CANCER RESEARCH; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; EUROPE; FATIGUE; HUMAN; METHODOLOGY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ORGANIZATION; PRIORITY JOURNAL; SOUTHERN EUROPE; THROMBOCYTOPENIA; UNITED KINGDOM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS; DNA REPAIR; DRUG DESIGN; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; EUROPE; HUMANS; INTERNATIONAL AGENCIES; MEDICAL ONCOLOGY; NEOPLASM PROTEINS; RESEARCH; RIBOSOMES;

EID: 0037217237     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120016408     Document Type: Article

References (49)

1. Finley, G.J.; Riou, J.-F.; Baguley, B.C. From amsacrine to XR5000 (N-[2-(dimethylamino)ethyl]acridine 4-carboxinamide): selectivity for topoisomerase I and II among acridine derivatives. Eur. J. Cancer 1996. 32A (4), 708-714.
2. Baguley, B.C.; Finlay, G.J. Pharmacokinetic/cytokinetic principles in the chemistry of solid tumors. Clin. Exp. Pharmacol. Physiol. 1995, 22, 825-828.
3. Wall, M.E.; Wani, M.C.; Cook, C.E.; Palmer, K.H.; McPhai, A.T.; Sim, G.A. Plant antitumor agents. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88, 3888-3890.
4. Zanna, C.; et al. Potent and less schedule-dependent antitumor activity of the oral camptothecin derivative ST1481. Proceedings of ASCO, 37th Annual Meeting, San Francisco, 2001; Vol. 20, abs # 406, 102-A
5. Bos, A.M.E.; et al. A phase I study of NX211 (liposomal lurtotecan) given as IV infusion on day 1 every 3 weeks in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 2000, 19, 768.
6. Rothemberg, M.L.; et al. Phase I evaluation of liposomal topoisomerase I inhibitor, NX211, given on days 1, 2 & 3 or days 1, 8 every 3 weeks to patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 2000, 19, 769.
7. D'Incalci, M.; Balconi, G.; Erba, E.; Bonfanti, M.; Filippeschi, S.; Garcia de Quesada, T.Jimeno, J.M. Antiproliferative activity and mode of action of novel compounds of marine origin. Eur. J. Cancer 1995, 31A (108), 26.
8. Le Cesne, A. Phase II study of ET743 in advanced soft tissue sarcoma in adults. A STBSG-EORTC trial. ASCO Proceedings, 2000; abstract 2182.
9. Erba, E.; Di Liberti, G.; Tiozzo, G.; Ubazio, P.; Fircloth, G.; Jimeno, J.; D'Incalci, M. Synergistic cytotoxic effect of ET-743 and cisplatinum. Clin. Cancer Res. 2000, 6 (Supplement), 4508s, Abs 209.
10. Patterson, L.H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastatis Rev. 1993, 1, 119-134.
11. Raleigh, S.M.; Wanogho, E.; Burke, M.D.; McKeown, S.R.; Patterson, L.H. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int. J. Radiat. Biol. Phys. 1998, 42, 763-767.
12. Chua, M.-S.; Kashiyama, E.; Stinson, S.F.; Bradshaw, T.D.; Sausville, E.A.; Stevens, M.F.G. CYP1A1 is an essential modulator of the anti-tumour properties of the novel agent 2-(4-amino-3-methylphenyl) benzothiazole (DF203, NSC 674495) in human breast cancer cells. Cancer Res. 2000, 60, 5196-5203.
13. Pohl, J.; et al. A sugar-linked ifosfamide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother. Pharmacol. 1995, 34, 364-370.
14. +-D-glucose cotransporter SAATI. Proc. Natl Acad. Sci. U.S.A. 1998, 95, 2914-2919.
15. Farrell, N.; et al. Chemical studies and DNA binding of charged polynuclear platinum complexes. Proc. Am. Assoc. Cancer Res. 1997, 38, 310.
16. Sessa, C.; Capri, G.; Gianni, L.; Peccatori, F.; Grasselli, G.; Bauer, J.; Zucchetti, M.; Vigano, L.; Gatti, A.; Minoia, C.; Liati, P.; Van den Bosch, S.; Bernareggi, A.; Camboni, G.; Marsoni, S. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR 3464, a novel cationic triplatinum complex. Ann. Oncol. 2000, in press.
17. Minotti, G.; Giancristofaro, G.; Menna, P.; Salvatorelli, E.; Licata, S.; Gianni, L. Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 18879. Proceedings of 11th NCI-EORTC-AACR Symposium, Amsterdam, 2000; abs # 360, 115 pp.
18. Beeram, M.; Hidalgo, M.; Rodriguez, G.; et al. A phase 1 and pharmacokinetic (PK) study of the novel taxane BMS 184476 administered as 1-hour intravenous (IV) infusion weekly. Proceedings of ASCO, 37th Annual Meeting, San Francisco, 2001; Vol. 20, abs # 421.
19. Sessa, C.; Capri, G.; Lladò, A.; Grasselli, G.; Perotti, A.; Viganò, L.; Locatelli, A.; Peccatori, F.; Renard, J.; Voi, M.; Gallant, G.; Colombini, S.; Marsoni, S.; Gianni, L. A dose finding/pharmacokinetic trial of the novel taxane BMS-184476 in combination with doxorubicin (DOX). Proceedings of ASCO, 37th Annual Meeting, San Francisco, 2001; Vol. 20, abs # 423, 107 pp.
20. Bollag, D.; McQueney, P.A.; Zhu, J.; et al. Epothilones, a new class of microtubule-stabilizing agents with a TAXOL®-like mechanism of action. Cancer Res. 1995, 55, 2325-2333.
21. Bishop, W.R.; et al. Normal triocyclic inhibitors of farnesyl protein transferase: biochemical characterization and inhibition of ras modification in transfected Cos cells. J. Biol. Chem. 1995, 270, 30611-30618.
22. Talpaz, M.; et al. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemia, including chronic myelogenous leukemia in blast crisis. ASCO Proceedings, 2000; abstract 6.
23. Petit, G.R.; Singh, S.B.; Hamel, E.; Lin, C.M.; Alberts, D.S.; Garcia-Kendall, D. Isolation and structure of the strong growth and tubulin inhibitor combretastatin A-4. Experentia 1989, 45, 209-211.
24. Petit, G.R.; Cragg, G.M.; Herald, D.L.; Schmidt, J.M.; Lohavanijaya, P. Isolation and structure of combretastatin. Can. J. Chem. 1982, 60, 1374-1376.
25. Denekamp, J.; Hill, S.A. Angiogenic attack as a therapeutic strategy for cancer. Radiother. Oncol. 1991, 20 (suppl.)103-112.
26. Bibby, M.C.; Double, J.A.; Loadman, P.M.; Duke, C.V. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J. Natl Cancer Inst. 1989, 81, 216-220.
27. Zwi, L.J.; Baguley, B.C.; Gavin, J.B.; Wilson, W.R. Blood flow failures as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J. Natl Cancer Inst. 1989, 81, 1005-1013.
28. Mahadevan, V.; Malik, S.T.A.; Meager, A.; Fiers, W.; Lewis, G.P.; Hart, E.I. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res. 1990, 50, 5537-5542.
29. Rewcastle, G.W.; Atwell, G.J.; Baguley, B.C.; Calveley, S.B.; Denny, W.A. Potential antitumor agents. Synthesis and structure activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J. Med. Chem. 1989, 32, 793-799.
30. Rewcastle, G.W.; Atwell, G.J.; Baguley, B.C.; Boyd, M.; Thomsen, L.L.; Zhuang, L.; Denny, W.A. Potential antitumor agents. Structure activity relationships for side chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. J. Med. Chem. 1991, 34, 2864-2870.
31. Asano, M.; Yukita, A.; Matsumoto, T.; et al. An antihuman VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998, 17, 185-189.
32. Presta, L.; Chen, H.; O'Connor, S.; et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57, 4593-4599.
33. Jenkins, B.J.; Nauth-Misir, R.R.; Martin, J.E.; Fowler, C.G.; Hope-Stone, H.F.; Blandy, J.P. The fate of G3pT1 bladder cancer. Br. J. Urol. 1989, 64, 608-610.
34. Quilty, P.M.; Duncan, W. Treatment of superficial (T) tumors of the bladder by radical radiotherapy. Br. J. Urol. 1986, 5, 147-152.
35. Hodge, J.P.; Schlom, J.; et al. A recombinant vaccinia virus expressing human prostate specific antigen (PSA) safety and immunogenicity in a non human primate. Int. J. Cancer 1995, 63, 231-237.
36. Hodge, J.W.; MvLaughlin, J.P.; et al. Admixture of recombinant virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in antitumor immunity. Cancer Res. 1995, 55, 3598-3603.
37. Walboomers, J.M.M.; DeRoda Husman, A.-M.; Van Den Brule, A.J.C.; Sniljders, P.J.F.; Meijer, G.J.L.M. Human Papillomaviruses and Cervical Cancer: Biology and Immunology; Stern, P.L., Stanley, M.A., Eds.; Oxford University Press: Oxford, 1994; 41-71.
38. Bagshawe, K.D.; Springer, C.J.; Searle, F.; et al. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 1988, 58, 700-703.
39. Bagshawe, K.D. Towards generating cytotoxic drugs at cancer sites. Br. J. Cancer 1989, 60, 275-281.
40. Bagshawe, K.D. Antibody-directed prodrug therapy (ADEPT). Adv. Pharmacol. 1993, 24, 99-121.
41. Eck, J.; Langer, M.; Möckel, B.; Witthohn, K.; Zinke, H.; Lentzen, H. Characterisation of recombinant and plant derived mistletoe lectin and their B-chains. Eur. J. Biochem. 1999, 265, 788-797.
42. Whitesell, L.; Mimnaugh, E.G.; De, C.B.; Myers, C.E.; Neckers, L.M. Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl Acad. Sci. U.S.A. 1994, 91, 8324.
43. Schulte, T.W.; Neckers, L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to Hsp90 and shares important biological activites with geldanamycin. Cancer Chemother. Pharmacol. 1998, 42, 273-279.
44. 5-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl Acad. Sci. U.S.A. 1990, 87, 5368-5372.
45. 6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun. 1990, 2, 371-377.
46. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991, 51, 3367-3372.
47. Bradshaw, T.D.; Shi, D.-F.; Schultz, R.D.; Paull, K.D.; Kelland, L.; Wilson, A.; Garner, C.; Fiebig, H.H.; Wrigley, S.; Stevens, M.F.G. Influence of 2-(4-aminophenyl) benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo. Br. J. Cancer 1998, 78, 421-429.
48. Bradshaw, T.D.; Wrigley, S.; Shi, D.-F.; Schultz, R.D.; Paull K.D.; Stevens, M.F.G. 2-(4-aminophenyl) benzothiazoles: novel agents with selective profiles of in vitro anti-tumor activity. Br. J. Cancer 1998, 77, 745-752.
49. Chua, M.S.; Bradshaw, T.D.; Stevens, M.F.G. 2-(4-aminophenyl) benzothiazoles: agents with selective and potent anti-tumor activity in vitro and in vivo. In Contributions to Oncology; Fiebig, H.H., Burger, A.M., Eds.; Basel: Karger, 1999; Vol. 54, 397-408.